The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Evaluating next-generation immunotherapies in earlier lines of treatment in multiple myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares her excitement for clinical trials evaluating next-generation immunotherapies including CAR-T therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) in earlier lines of treatment in patients with multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
